KOSDAQBiotech & Pharma032300

Korea Pharma

₩7,590 0.00%2026-11-18 close
Market Cap
₩82.8B
Turnover
₩79,720,810
Volume
10K
Shares out.
10.9M
PER
46.0×
PBR
1.1×
EPS
₩167
Dividend Yield
0.65%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

CMO Growth Drives Profit Recovery; Durability Is the Test

Korea Pharma returned to operating profit in the first quarter of 2026 on contract manufacturing (CMO) growth and lower cost ratios, and whether that recovery holds in the next annual report is the next test.

  1. 1

    Operating profit in the third quarter of 2026 was KRW 3.19 billion, up 47.3% from the prior quarter, and every quarter since the first quarter of 2026 has shown an operating profit.

  2. 2

    Cumulative CMO revenue through the third quarter of 2026 reached KRW 20.6 billion, up 31% year on year and about 27% of total sales (company announcement, November 12, 2026).

  3. 3

    For 2025, the company posted an operating loss of KRW 887 million and a net loss attributable to controlling shareholders of KRW 2.64 billion, after a controlling-shareholder net profit of KRW 3.79 billion in 2024.

  4. 4

    The debt-to-equity ratio rose to 84.1% at the end of 2025 from 57.3% in 2024, and operating cash flow fell to KRW 2.69 billion in 2025 from KRW 8.05 billion in 2024.

  5. 5

    Over the most recent four quarters (Q4 2025 to Q3 2026), net profit attributable to controlling shareholders totaled KRW 1.82 billion, so the track record of profit since the turnaround remains short.

02

Business structure

Korea Pharma is a specialty pharmaceutical company focused on central nervous system (CNS) disorders, running two main lines: sales of its own prescription drugs and contract manufacturing (CMO).

By business segment as of the second quarter of 2026, CNS products accounted for 26% of sales, contracted products for 18%, merchandise for 16%, digestive products for 16%, and other items for 14% (corporate data aggregator). CNS is therefore the largest segment.

Cumulative CMO revenue through the third quarter of 2026 reached KRW 20.6 billion, up 31% year on year and about 27% of total sales (company announcement, November 12, 2026). Pharmaceutical sales rose 3.4% to KRW 45.0 billion, and export sales were KRW 2.0 billion.

Among key products, Algen and Krirol grew 35% and 75% year on year, while Sertraline and Arabil rose 13% and 18%. Merchandise sales depend on third-party products, and they shrank after contract terminations and discontinued sales of some products that lacked competitiveness in early 2024.

On the proprietary side, the company expanded its portfolio in 2024 with desvenlafaxine extended-release tablets, divalproex extended-release tablets, and Albix tablets. On production, ointment line utilization rose from 39.3% in 2024 to 45.8% in 2025 and 74.4% cumulative through the third quarter of 2026.

Compared with large CMO operators such as Samsung Biologics, the scale of Korea Pharma's contract manufacturing is small.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24B₩500M2.1%
2025Q4₩19.4B-₩2.3B−11.9%
2026Q1₩24.6B₩1.3B5.3%
2026Q2₩25.9B₩2.2B8.4%
2026Q3₩26.5B₩3.2B12.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩81B₩6.2B-₩1.1B7.6%−1.9%118.9%
2023₩83.2B₩6.3B₩83,763,7057.5%0.1%76.9%
2024₩81.3B₩6.1B₩3.8B7.5%5.3%57.3%
2025₩87.6B-₩900M-₩2.6B−1.0%−3.8%84.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue was KRW 81 billion in 2022, KRW 83.2 billion in 2023 (up 2.7% year on year), KRW 81.3 billion in 2024 (down 2.4%), and KRW 87.6 billion in 2025 (up 7.8%), with 2025 the largest year and 2022 the smallest in the 2022 to 2025 period.

Operating profit was KRW 6.19 billion in 2022, KRW 6.27 billion in 2023 (up 1.3%), and KRW 6.09 billion in 2024 (down 2.9%), with operating margins of 7.6%, 7.5%, and 7.5%. In 2025 the company recorded an operating loss of KRW 887 million, and its operating margin was -1.0%.

The company attributed the main drivers of the 2025 swing to channel diversification and initial costs from new product launches (March 2026 disclosure report).

At the third-quarter 2025 results, the company also cited competition in some product lines and R&D expenses at the regulatory approval stage of a new product as temporary pressure on profitability.

Net profit attributable to controlling shareholders was a loss of KRW 1.12 billion in 2022, KRW 83.76 million in 2023 (a swing to profit), and KRW 3.79 billion in 2024 (up 4,426.7%), before returning to a loss of KRW 2.64 billion in 2025.

Net profit including non-controlling interests was also a loss of KRW 2.64 billion in 2025. By quarter, the third quarter of 2025 showed revenue of KRW 24 billion, operating profit of KRW 507 million, and a controlling-shareholder net loss of KRW 20.9 million.

In the fourth quarter of 2025, revenue fell 19.0% quarter on quarter to KRW 19.4 billion, the company posted an operating loss of KRW 2.31 billion, and the controlling-shareholder net loss widened to KRW 2.76 billion.

In the first quarter of 2026, revenue rose 26.6% to KRW 24.6 billion and operating profit turned positive at KRW 1.31 billion, with controlling-shareholder net profit of KRW 682 million.

In the second quarter of 2026, revenue was KRW 25.9 billion, operating profit KRW 2.16 billion (up 65.8% quarter on quarter), and controlling-shareholder net profit KRW 1.32 billion.

In the third quarter of 2026, revenue was KRW 26.5 billion, operating profit KRW 3.19 billion (up 47.3% quarter on quarter and up 528.7% year on year), and controlling-shareholder net profit KRW 2.58 billion, a swing to profit from the prior year.

Cumulative gross cost of sales through the third quarter of 2026 was 60.7% of revenue, down 1.5 percentage points year on year, and selling and administrative expenses fell by KRW 700 million to KRW 23.6 billion (company announcement, November 12, 2026).

Operating profit grew much faster than revenue because both the cost ratio and the selling expense ratio declined.

05

Industry analysis

For Korea Pharma, the main growth axis in domestic prescription drugs is the expansion of the central nervous system (CNS) treatment market. At its first-quarter 2026 results briefing, company officials said they would strengthen the related portfolio in line with CNS market growth.

In the same first-quarter 2026 explanation, rising demand for ADHD treatments and stronger digestive-system products were cited as sales drivers. By contrast, the third-quarter 2025 briefing pointed to heightened competition in some product lines as a factor weighing on profitability.

On production capacity, higher utilization of the ointment and tablet lines improves absorption of fixed costs. Tablet line utilization reached 71.9% cumulative through the third quarter of 2026, up 7.6 percentage points from the prior year.

Large CMO operators such as Samsung Biologics handle global volumes on far larger capacity, whereas Korea Pharma's contract manufacturing is mid-sized and built around domestic and partner clients.

In a domestic generics-oriented market, pricing and cost pressure are persistent, so cost-ratio management is a central variable for profitability. Company-specific utilization and contract volumes, rather than the industry cycle alone, will largely determine the direction of results.

06

Outlook

At its 2026 New Year ceremony, the company set out core product competitiveness, portfolio diversification, quality and production stability, and organizational capability as its management priorities.

At the third-quarter 2025 results briefing, it said it would gradually improve profitability through cost efficiency and by maximizing the results of its key pipeline.

At the first-quarter 2026 results briefing, it said the potential for revenue growth through external partnerships had been confirmed and that it would actively seek new customers and strategic products.

Contract manufacturing revenue rose 31% through the third quarter of 2026 and has become the main driver of profit improvement.

On production, tablet output reached 172.55 million units through the third quarter of 2026, and one press analysis (Daily Pharm) suggested full-year output could exceed the 2025 total of 224.98 million units if the current pace continues.

On shareholder returns, a KRW 1 billion treasury share acquisition trust contract runs until April 6, 2027. However, changes in merchandise contracts and initial costs of new products could move quarterly profit, so the pace of the stated profitability recovery needs quarter-by-quarter confirmation.

The next checkpoint is the operating margin and operating cash flow in the 2026 annual report, against the 2025 disclosed figures of -1.0% and KRW 2.69 billion.

07

Valuation

PER
46.0×
PBR
1.1×
ROE
2.5%
EPS
₩167
BPS
₩6,986
Dividend per share
₩50

The share price should be read together with the size of earnings. Over the most recent four quarters, net profit attributable to controlling shareholders totaled KRW 1.82 billion, so the price-to-earnings multiple is sensitive to small changes in profit.

During the 2025 full-year net loss, the earnings multiple could not be meaningfully applied, and as profitability returned in 2026 the base for that calculation is taking shape. The price-to-book ratio sits in a range where the market values the company above its book equity.

Shareholders' equity was KRW 68.8 billion at the end of 2025, of which all was attributable to controlling shareholders, and profit generated relative to that equity base is still modest. The cash dividend yield is below the industry average, and the dividend amount is small.

On the other hand, the company redeemed KRW 5.0 billion of convertible bonds in August 2026, and cash and cash equivalents stood at KRW 28.8 billion at the end of September 2026, which indicates financial cushion. Multiples are likely to stabilize as more profitable quarters build a thicker earnings base.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

CMO growth

Contract manufacturing revenue reached KRW 20.6 billion through the third quarter of 2026, up 31% year on year and about 27% of total sales (company announcement, November 12, 2026). Ointment line utilization rose from 39.3% in 2024 to 45.8% in 2025 and 74.4% cumulative through the third quarter of 2026 (Daily Pharm).

The company said it had confirmed the potential for revenue growth through external partnerships. Higher utilization of its own lines is appearing alongside rising contracted volumes.

Lower cost and SG&A ratios

Cumulative gross cost of sales through the third quarter of 2026 was 60.7% of revenue, down 1.5 percentage points year on year, and the selling and administrative expense ratio fell from 35.7% to 30.6% (company announcement, November 12, 2026).

Over the same period the operating margin rose 6.6 percentage points to 8.7%. Revenue grew 12.9% while costs fell, so profit growth far outpaced sales growth. The shift from the 2025 annual operating margin of -1.0% shows this change in structure.

Broad growth in core products

Sales of Algen and Krirol rose 35% and 75% year on year through the third quarter of 2026, and Sertraline and Arabil rose 13% and 18% (company announcement, November 12, 2026). CNS products are the largest segment at 26% of sales as of the second quarter of 2026.

The company attributed part of its growth to rising demand for ADHD treatments. Growth across several key products suggests that results do not rest on a single product.

09

Bear factors

A short record of profit

In the fourth quarter of 2025 the company posted an operating loss of KRW 2.31 billion and a net loss attributable to controlling shareholders of KRW 2.76 billion. The period of accumulated quarterly profit since the first quarter of 2026 is still short.

Net profit attributable to controlling shareholders over the most recent four quarters totaled KRW 1.82 billion, small relative to 2025 annual revenue of KRW 87.6 billion. Whether the quarterly profits are temporary or structural will need to be confirmed with more quarters of results.

Volatility in merchandise sales

Merchandise sales depend on third-party products, and in early 2024 contract terminations and discontinued sales of some products left a revenue gap. Cumulative merchandise sales through the third quarter of 2026 reached KRW 11.0 billion, up 11.5%, but the segment was 16% of sales as of the second quarter of 2026.

Changes in external contracts can directly affect results. Filling such gaps with proprietary launches depends on initial launch costs and approval timelines.

Rising financial burden

The debt-to-equity ratio rose from 57.3% in 2024 to 84.1% in 2025, and total liabilities were KRW 57.9 billion at the end of 2025. Operating cash flow fell from KRW 8.05 billion in 2024 to KRW 2.69 billion in 2025.

Total equity held at KRW 68.8 billion, but after the swing to loss, the pace at which profit rebuilds equity is the key question. The treasury share trust is a shareholder-return step, but it should be read alongside cash capacity.

10

Risk factors

Concentration risk

CNS products are the largest segment, so changes in prescribing conditions in a single therapeutic area would feed directly into results. The stability of external merchandise contracts is another variable, as the early-2024 contract terminations showed.

The company has presented an expansion of its CNS-focused portfolio and digital healthcare business as growth strategies.

Regulatory approval and launch costs

Launching new products can bring R&D expenses at the regulatory approval stage and initial costs, which can temporarily weigh on profitability. At the third-quarter 2025 results, the company described these as temporary factors. If approval timelines slip, the cost burden flows directly into quarterly results. Until new product sales scale up, cost and SG&A control serves as the main defense for profit.

Cash flow and financial buffer

Operating cash flow fell to KRW 2.69 billion in 2025 from KRW 8.05 billion in 2024, and the debt-to-equity ratio rose to 84.1%. On the other hand, the company redeemed KRW 5.0 billion of convertible bonds in August 2026, and cash and cash equivalents stood at KRW 28.8 billion at the end of September 2026.

Whether cash generation improves alongside profit will determine whether this financial risk eases. The cash flow statement in the next annual report will show this.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. Whether the full-year operating margin, operating cash flow, and debt-to-equity ratio move away from the disclosed 2025 values of -1.0%, KRW 2.69 billion, and 84.1% will indicate how durable the profit recovery is.

  2. Before April 6, 2027

    Execution of the KRW 1 billion treasury share acquisition trust contract, which runs until April 6, 2027. The pace of execution will show how the company carries out its shareholder-return plan.

  3. Mid-May 2027 (based on the timing of the first-quarter 2026 release)

    First-quarter 2027 results. This is where to check whether operating profit continues after the first-quarter 2026 turnaround and whether contract manufacturing revenue keeps growing year on year.

12

Overall view

Korea Pharma swung to an annual operating loss in 2025, and quarterly operating profit has been positive since the first quarter of 2026. Operating profit rose to KRW 3.19 billion in the third quarter of 2026, with contract manufacturing growth and lower cost and SG&A ratios at the center of the improvement.

The operating margin, which held in the 7% range from 2022 to 2024, fell to -1.0% in 2025 and has since started to recover. Balanced growth across CNS-focused products and higher utilization of the ointment and tablet lines are supportive factors.

On the other side, net profit attributable to controlling shareholders over the most recent four quarters totaled only KRW 1.82 billion, so the profit base remains thin, and merchandise sales are exposed to external contract changes.

The debt-to-equity ratio rose to 84.1% in 2025, so the financial burden also needs monitoring. Cash and cash equivalents of KRW 28.8 billion at the end of September 2026 and the convertible bond redemption provide a financial cushion.

The next checkpoints are the operating margin and cash flow in the 2026 annual report and the first-quarter 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. thevc.kr
  4. butler.works
  5. news.nate.com
  6. sedaily.com
  7. asiae.co.kr
  8. edaily.co.kr
  9. edaily.co.kr
  10. medicopharma.co.kr
  11. m.news.nate.com
  12. newspim.com
  13. fnnews.com
  14. newstown.co.kr
  15. dailypharm.com
  16. wowtv.co.kr
  17. msn.com
  18. edaily.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis